Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
ELEVATEA Phase 1b/2, Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) | |
|---|---|
| Local Project Reference: | 158415 |
| Principal Investigator | Dr Rebecca Roylance |
| Drug Class/ Treatment: | Elacestrant (Estrogen Receptor Antangonist) + Various Combination |
| Patient Population: | ER+, HER2– Breast Cancer |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
ELECTRA (ELA-0121)A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic | |
|---|---|
| Local Project Reference: | 151443 |
| Principal Investigator | Dr Elisavet Papadimitraki |
| Drug Class/ Treatment: | Elacestrant (Oral selective ER degrader) |
| Patient Population: | Women and men with brain metastasis from estrogen receptor positive, her-2 negative breast cancer |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
